Research programme: breast cancer vaccine - CEL-SCI/Northeast Ohio Medical University

Drug Profile

Research programme: breast cancer vaccine - CEL-SCI/Northeast Ohio Medical University

Alternative Names: J-HER vaccine - CEL-SCI/Northeast Ohio Medical University; J-HER vaccine - CEL-SCI/Northeastern Ohio Universities College of Medicine

Latest Information Update: 27 Oct 2014

Price : $50

At a glance

  • Originator CEL-SCI Corporation; Northeast Ohio Medical University
  • Developer CEL-SCI Corporation
  • Class Cancer vaccines
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 27 Oct 2014 Preclinical development is ongoing in USA
  • 31 Jan 2013 Preclinical trials in Breast cancer in USA (Parenteral)
  • 31 Jan 2013 Preclinical trials in Breast cancer (prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top